🟢 Vera Therapeutics surges 10% after FDA publishes favorable review of Trutakna and investors reassess Q2 results

Vera Therapeutics (VERA) stock is trading 9.93% up at $31.76 today. - The surge follows the FDA's publication of a favorable integrated review of Trutakna, its recently approved kidney disease therapy. - Investors are also reassessing the company's Q2 2026 results, which reported a narrower-than-expected loss on August 10, 2026.